SLC5A2 and diabetes mellitus: In addition to using SGLT2 inhibitors to treat biomarkers of diabetes, the present study elucidates how this strategy not only treats diabetes but also simultaneously promotes cardiovascular protection against future impairments to coronary microvascular function, diastolic function, myocardial lipid, and epicardial adipose tissue volume and composition when initiated early.